Program
SSGJ-613
A development code. Also written as “SSGJ-613 100 mg Q12W”, “SSGJ-613 200 mg Q12W” and “SSGJ-613 100 mg Q4W”.
Its studies are mostly in Arthritis, Gouty · Arthritis, Juvenile, led by 3SBio.
Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| 3SBio | 32 open or running | phase 2since Jul 12, 2026 | Aug 17, 2021 | Aug 11, 2027phase 2 · NCT07708181 |
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
- Aug 17, 2021First study: phase 1 study in Arthritis, JuvenileFirst studyNCT05027373 · 34 enrolled · China
- Jul 20, 2023Phase 1 study in Arthritis, GoutyNCT05966701 · 36 planned · China
- Jul 12, 2026Phase 2 study in Arthritis, GoutyPhase 2 reachedNCT07708181 · 200 planned
Ahead
- Aug 11, 2027Primary completion: phase 2 study in Arthritis, GoutyNCT07708181
TargetBeta
Not stated by its company or a source we have read. Most early programs say nothing of it.
Studies
All 3 led by companies developing it, newest first. Each opens its study page.
| Study | Phase | Status | Primary completion | Size |
|---|---|---|---|---|
| NCT07708181Arthritis, Gouty | 2 | Not yet recruiting | Aug 11, 2027 | 200 |
| NCT05966701Arthritis, Gouty · China | 1 | Not yet recruiting | Mar 10, 2024 | 36 |
| NCT05027373Arthritis, Juvenile · China | 1 | UNKNOWN | Apr 30, 2022 | 34 |
How it is read
Names in the registry
- “SSGJ-613”, 2 entries
- “SSGJ-613 100 mg Q12W”, 1 entry
- “SSGJ-613 200 mg Q12W”, 1 entry
- “SSGJ-613 100 mg Q4W”, 1 entry
Codes read as this program: SSGJ613.
Conditions, from the studies’ own filings
- Arthritis, Gouty, 2 studies
- Arthritis, Juvenile, 1 study
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.